There are two clinical trials listed for 212Pb, with a phase 1 safety study using [212Pb]Pb-TCMC-trastuzumab in patients with HER2-expressing ovarian cancer confined to the peritoneal cavity. The gene discussed is ERBB2; the disease is ovarian carcinoma.